BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2154734)

  • 1. Interactions between Epstein-Barr virus (EBV) and human cell lines: growth and EBV induction.
    Takimoto T; Iwawaki J; Tanaka S; Umeda R
    ORL J Otorhinolaryngol Relat Spec; 1990; 52(1):40-6. PubMed ID: 2154734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary EBV infection of human umbilical cord lymphocytes and EBV genome-negative lymphoblastoid cell lines (BJAB and Ramos).
    Takimoto T; Sato H; Ogura H
    Auris Nasus Larynx; 1986; 13(3):199-205. PubMed ID: 3036055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines.
    Béchet JM; Guétard D
    Int J Cancer; 1983 Jul; 32(1):61-5. PubMed ID: 6305854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus type 1 infection of isogenic Epstein-Barr virus genome-negative and -positive Burkitt's lymphoma-derived cell lines.
    Leinbach SS; Summers WC
    J Virol; 1979 Apr; 30(1):248-54. PubMed ID: 225521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
    Fresen KO; Hausen H
    Int J Cancer; 1976 Feb; 17(2):161-6. PubMed ID: 175026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of Epstein-Barr virus. IV. Induction of a specific antigen by EBV from two transformed marmoset cell lines in Ramos cells.
    Fresen KO; Cho MS; zur Hausen H
    Int J Cancer; 1978 Aug; 22(2):160-5. PubMed ID: 81181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular size variation of EBNA is determined by the EB viral genome.
    Gergely L; Sternås L; Dillner J; Klein G
    Intervirology; 1984; 22(2):85-96. PubMed ID: 6090339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The difference in tumorigenicity between Epstein-Barr virus (EBV) genome-positive and genome-negative epithelial hybrid cell lines derived from the human nasopharynx.
    Takimoto T; Sato H; Ogura H; Tanaka S; Umeda R
    Laryngoscope; 1988 Dec; 98(12):1334-8. PubMed ID: 2849005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
    Takimoto T; Sato H; Ogura H; Miyawaki T; Glaser R
    Cancer Res; 1986 May; 46(5):2541-4. PubMed ID: 3008992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transforming prototype of Epstein-Barr virus (B95-8) is also a lytic virus.
    Glaser R; Tarr KL; Dangel AW
    Int J Cancer; 1989 Jul; 44(1):95-100. PubMed ID: 2545637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of a biologically active Epstein-Barr virus from nonproducer cells.
    Takimoto T; Sato H; Ogura H; Glaser R
    Cancer Res; 1986 Apr; 46(4 Pt 2):2085-7. PubMed ID: 3004720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies on growth characteristics of Epstein-Barr virus (EBV) genome-positive and -negative epithelial hybrid cell lines.
    Takimoto T; Tanaka S; Ishikawa S; Masuda K; Umeda R
    Laryngoscope; 1989 Jul; 99(7 Pt 1):741-3. PubMed ID: 2545984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative and quantitative analyses of Epstein-Barr virus early antigen diffuse component by western blotting enzyme-linked immunosorbent assay with a monoclonal antibody.
    Lin JC; Choi EI; Pagano JS
    J Virol; 1985 Mar; 53(3):793-9. PubMed ID: 2983091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue of transforming Epstein-Barr virus (EBV) from EBV-genome-positive epithelial hybrid cells transfected with subgenomic fragments of EBV DNA.
    Stoerker J; Glaser R
    Proc Natl Acad Sci U S A; 1983 Mar; 80(6):1726-9. PubMed ID: 6300871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible DNA-RNA tumor virus interaction in human lymphomas: expression of retroviral proteins in Ramos lymphoma lines is enhanced after conversion with Epstein-Barr virus.
    Lasky RD; Troy FA
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):33-7. PubMed ID: 6320170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
    Klein G; Ehlin-Henriksson B; Schlossman SF
    J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of target antigen for Epstein-Barr virus-specific cytotoxic T cells on BJAB cells freshly infected with EBV.
    Sugamura K; Tanaka Y; Hinuma Y
    Microbiol Immunol; 1982; 26(7):575-83. PubMed ID: 6290853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-inducing ability of herpesvirus papio in human and baboon lymphoma lines, compared to Epstein-Barr virus.
    Klein G; Falk L; Falk K
    Intervirology; 1978; 10(3):153-64. PubMed ID: 210135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of the lymphoma line "BJAB" by Epstein-Barr virus into phenotypically altered sublines is accompanied by increased c-myc mRNA levels.
    Wennborg A; Aman P; Saranath D; Pear W; Sümegi J; Klein G
    Int J Cancer; 1987 Aug; 40(2):202-6. PubMed ID: 3038758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marmoset lymphoblastoid cells transformed by NPC-KT-derived Epstein-Barr virus which possesses transforming and superinfecting characteristics.
    Takimoto T; Sato H; Ogura H; Ogura T; Ishikawa S; Iwawaki J
    ORL J Otorhinolaryngol Relat Spec; 1987; 49(4):169-74. PubMed ID: 2819802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.